AlphaStar Capital Management LLC Sells 264 Shares of Novo Nordisk A/S (NYSE:NVO)

AlphaStar Capital Management LLC cut its position in Novo Nordisk A/S (NYSE:NVO) by 10.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,244 shares of the company’s stock after selling 264 shares during the period. AlphaStar Capital Management LLC’s holdings in Novo Nordisk A/S were worth $320,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also bought and sold shares of the business. First PREMIER Bank bought a new stake in shares of Novo Nordisk A/S in the 1st quarter worth about $25,000. 1620 Investment Advisors Inc. purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth approximately $25,000. Dixon Mitchell Investment Counsel Inc. bought a new stake in Novo Nordisk A/S during the 1st quarter valued at $26,000. Orion Capital Management LLC purchased a new position in Novo Nordisk A/S in the first quarter valued at about $26,000. Finally, Gilliland Jeter Wealth Management LLC raised its stake in shares of Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after acquiring an additional 120 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.3 %

NYSE:NVO traded down $0.37 on Tuesday, reaching $134.93. The company’s stock had a trading volume of 1,292,526 shares, compared to its average volume of 4,392,370. The firm has a market cap of $605.50 billion, a price-to-earnings ratio of 46.52, a price-to-earnings-growth ratio of 1.33 and a beta of 0.41. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. Novo Nordisk A/S has a 12-month low of $86.96 and a 12-month high of $148.15. The stock has a 50 day moving average price of $136.12 and a 200 day moving average price of $131.78.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were paid a $0.5126 dividend. This represents a dividend yield of 0.7%. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 24.83%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on NVO shares. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 19th. Argus boosted their target price on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. BMO Capital Markets cut their price objective on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Monday, August 19th. Finally, The Goldman Sachs Group began coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They set a “buy” rating and a $156.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $145.17.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.